NO2025014I1 - Delgocitinib in all forms protected by the basic patent - Google Patents

Delgocitinib in all forms protected by the basic patent

Info

Publication number
NO2025014I1
NO2025014I1 NO2025014C NO2025014C NO2025014I1 NO 2025014 I1 NO2025014 I1 NO 2025014I1 NO 2025014 C NO2025014 C NO 2025014C NO 2025014 C NO2025014 C NO 2025014C NO 2025014 I1 NO2025014 I1 NO 2025014I1
Authority
NO
Norway
Prior art keywords
delgocitinib
basic patent
forms protected
protected
forms
Prior art date
Application number
NO2025014C
Other languages
English (en)
Norwegian (no)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2025014(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO2025014I1 publication Critical patent/NO2025014I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO2025014C 2009-07-31 2025-03-04 Delgocitinib in all forms protected by the basic patent NO2025014I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31

Publications (1)

Publication Number Publication Date
NO2025014I1 true NO2025014I1 (no) 2025-03-04

Family

ID=43529436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2025014C NO2025014I1 (no) 2009-07-31 2025-03-04 Delgocitinib in all forms protected by the basic patent

Country Status (36)

Country Link
US (4) US8609647B2 (enExample)
EP (3) EP3181570A1 (enExample)
JP (9) JP5520158B2 (enExample)
KR (1) KR101773208B1 (enExample)
CN (1) CN102510865B (enExample)
AR (1) AR077497A1 (enExample)
AU (1) AU2010278066B2 (enExample)
BR (1) BR112012002157B1 (enExample)
CA (1) CA2767899C (enExample)
CO (1) CO6491052A2 (enExample)
CY (2) CY1118747T1 (enExample)
DK (1) DK2460806T3 (enExample)
ES (1) ES2616705T3 (enExample)
FI (1) FIC20250012I1 (enExample)
FR (1) FR25C1010I2 (enExample)
HR (1) HRP20170447T1 (enExample)
HU (2) HUE033070T2 (enExample)
IL (1) IL217048A (enExample)
LT (2) LT2460806T (enExample)
ME (1) ME02667B (enExample)
MX (1) MX2012001313A (enExample)
MY (1) MY163495A (enExample)
NL (1) NL301321I2 (enExample)
NO (1) NO2025014I1 (enExample)
NZ (1) NZ597994A (enExample)
PE (1) PE20121276A1 (enExample)
PL (1) PL2460806T3 (enExample)
PT (1) PT2460806T (enExample)
RS (1) RS55913B1 (enExample)
RU (1) RU2630694C2 (enExample)
SG (1) SG176918A1 (enExample)
SI (1) SI2460806T1 (enExample)
SM (1) SMT201700166T1 (enExample)
TW (1) TWI466885B (enExample)
WO (1) WO2011013785A1 (enExample)
ZA (1) ZA201200689B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP5749341B2 (ja) * 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
PL2796460T3 (pl) 2011-12-21 2018-12-31 Jiangsu Hengrui Medicine Co. Ltd. Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CA2948444C (en) * 2014-05-28 2022-07-26 Astrazeneca Ab Processes for the preparation of azd5363 and intermediate used therein
EP3321271B1 (en) * 2015-07-07 2024-05-29 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DK3352734T3 (da) * 2015-09-24 2020-03-30 Japan Tobacco Inc Behandling af alopecia areata
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法
AU2017209932A1 (en) 2016-01-21 2018-07-05 Leo Pharma A/S Treatment of hand eczema
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
BR112019008812A2 (pt) * 2016-11-23 2019-07-16 Jiangsu Hengrui Medicine Co método de preparação para e intermediário de derivado de pirrolo anel heteroaromático de seis elementos
KR102702286B1 (ko) * 2016-12-21 2024-09-04 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 공결정
BR112019012210A2 (pt) 2016-12-21 2019-11-12 Japan Tobacco Inc formas cristalinas de um inibidor de janus cinase
MX2019007542A (es) 2016-12-21 2019-11-18 Japan Tobacco Inc Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos.
CN110291090A (zh) * 2017-01-20 2019-09-27 利奥制药有限公司 作为新型jak激酶抑制剂的双环胺
JP7101176B2 (ja) * 2017-02-03 2022-07-14 レオ ファーマ アクティーゼルスカブ 新規ＪＡＫキナーゼ阻害剤としての５－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）－５－アザスピロ［２．５］オクタン－８－カルボン酸誘導体
JP2020536898A (ja) * 2017-10-10 2020-12-17 バイオジェン インコーポレイテッド スピロ誘導体を調製するためのプロセス
AU2019215049A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2021528479A (ja) * 2018-07-06 2021-10-21 レオ ファーマ アクティーゼルスカブ ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
BR112021022031A2 (pt) 2019-05-15 2021-12-28 Leo Pharma As Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica
WO2021025129A1 (ja) * 2019-08-07 2021-02-11 ロート製薬株式会社 涙液分泌促進用眼科組成物
TWI889740B (zh) * 2019-12-27 2025-07-11 日商樂敦製藥股份有限公司 水性組成物
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
TW202241439A (zh) * 2020-12-29 2022-11-01 大陸商上海岸闊醫藥科技有限公司 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療
WO2024180493A1 (en) 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
AU2024238918A1 (en) 2023-03-17 2025-10-09 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2024225445A1 (en) 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
PL198640B1 (pl) * 1998-06-19 2008-07-31 Pfizer Prod Inc Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EA009789B1 (ru) * 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
KR20080016659A (ko) * 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
CN101563323B (zh) 2006-12-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
PE20090996A1 (es) * 2007-04-02 2009-07-15 Palau Pharma Sa Derivados de pirrolopirimidina como inhibidores de cinasa jak3
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野　信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Also Published As

Publication number Publication date
CA2767899C (en) 2018-08-28
RS55913B1 (sr) 2017-09-29
AU2010278066A1 (en) 2012-03-01
ES2616705T3 (es) 2017-06-14
HUS2500013I1 (hu) 2025-03-28
AR077497A1 (es) 2011-08-31
NL301321I2 (nl) 2025-07-17
FIC20250012I1 (fi) 2025-02-28
BR112012002157A2 (pt) 2020-08-18
AU2010278066B2 (en) 2016-04-14
HUE033070T2 (hu) 2017-11-28
NZ597994A (en) 2013-08-30
HRP20170447T1 (hr) 2017-05-19
EP2460806A4 (en) 2012-12-26
JP2011046700A (ja) 2011-03-10
JP2020033384A (ja) 2020-03-05
ZA201200689B (en) 2012-10-31
JP2014141516A (ja) 2014-08-07
CY2025008I2 (el) 2026-02-25
LTPA2025511I1 (enExample) 2025-03-25
PT2460806T (pt) 2017-02-27
KR20120051649A (ko) 2012-05-22
KR101773208B1 (ko) 2017-08-31
CY1118747T1 (el) 2017-07-12
MY163495A (en) 2017-09-15
CY2025008I1 (el) 2026-02-25
RU2630694C2 (ru) 2017-09-12
JP2025109780A (ja) 2025-07-25
CN102510865B (zh) 2015-04-15
US20240150367A1 (en) 2024-05-09
BR112012002157B1 (pt) 2022-02-08
PE20121276A1 (es) 2012-09-27
US20110136778A1 (en) 2011-06-09
FR25C1010I2 (fr) 2026-02-06
CA2767899A1 (en) 2011-02-03
US8609647B2 (en) 2013-12-17
JP5520158B2 (ja) 2014-06-11
CO6491052A2 (es) 2012-07-31
JP2021183653A (ja) 2021-12-02
US20140187534A1 (en) 2014-07-03
JP2016029104A (ja) 2016-03-03
JP2017019877A (ja) 2017-01-26
RU2012106344A (ru) 2013-08-27
EP3858349A1 (en) 2021-08-04
EP3181570A1 (en) 2017-06-21
DK2460806T3 (en) 2017-03-20
SG176918A1 (en) 2012-01-30
JP2023138641A (ja) 2023-10-02
WO2011013785A1 (ja) 2011-02-03
SI2460806T1 (sl) 2017-04-26
LT2460806T (lt) 2017-02-10
TWI466885B (zh) 2015-01-01
SMT201700166T1 (it) 2017-05-08
EP2460806B1 (en) 2017-01-04
EP2460806A1 (en) 2012-06-06
PL2460806T3 (pl) 2017-06-30
CN102510865A (zh) 2012-06-20
IL217048A0 (en) 2012-02-29
TW201107325A (en) 2011-03-01
MX2012001313A (es) 2012-02-29
FR25C1010I1 (fr) 2025-04-25
IL217048A (en) 2014-12-31
ME02667B (me) 2017-06-20
US20230023377A1 (en) 2023-01-26
JP2018111701A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
FIC20250012I1 (fi) Delgositinibi kaikissa peruspatentin suojaamissa muodoissa
NO2022003I1 (no) Vosoritide in all forms protected by the basic patent
FIC20230010I1 (fi) Sasitutsumabigovitekaani
NL301265I1 (nl) Quizartinib
HUE045331T2 (hu) Szikkasztótest
DK2430035T3 (da) Uracylspipooxetannukleosider
EP2281635A4 (en) CUTTER
DE112009005323A5 (de) Hebelarmprüfmaschine
BR112012004964A2 (pt) girocóptero
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
FI20095891A0 (fi) Polttomoottorisovitelma
DE112010004865T8 (de) Lamellennassreibkupplung
DE112010003255A5 (de) Fördergutverteiler
EP2518828A4 (en) Rfid tag
FI20090100A0 (fi) Biotinidaasimääritys
BR112012006693A2 (pt) combinação
EP2392475A4 (en) NECESSARY TO PAINT
BR112012006968A2 (pt) combinação
FI20090173A0 (fi) Pystypuun karsintalaite
FI20095429A0 (fi) Murskain
FI20095580A0 (fi) Kaivo
AT506924A3 (de) Bauprojektor
AT508508A3 (de) Heuballenbohrer
NO20091744L (no) Babylogger
PL389509A1 (pl) Bioanoda